Clinical trial
Open access
Oct 2026
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
Although the trial did not meet its prespecified efficacy endpoint, PFS in 6 subjects among this heavily pre-treated cohort highlight the need for biomarkers to select regimens for patients with recurrent ovarian cancer.
S. Adams, P. Gimotty, Teresa L. Rutledge et al.
· Nature Communications · 0 citations